期刊
JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 134, 期 2, 页码 319-325出版社
ELSEVIER SCIENCE INC
DOI: 10.1038/jid.2013.358
关键词
-
类别
资金
- National Institutes-of Health [R01-CA125103, R01-CA160495]
- Department of Defense [W81XWH-11-1-0385]
- Dr Miriam and Sheldon G Adelson Medical Research Foundation
- National Cancer Center
- Joanna M Nicolay Melanoma Foundation
In early 2011, we reviewed the initial success of the RAF inhibitor vemurafenib in mutant V600 BRAF melanoma patients. It was soon evident that the response to RAF inhibitor is heterogeneous and that the short-term benefits are burdened by the development of resistance. The field has progressed rapidly with the Food and Drug Administration approval of vemurafenib and the development of other RAF and MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase) inhibitors. Despite these advances, the issue of RAF inhibitor resistance remains. Here, we review recent clinical advances in the field, the growing number of resistance mechanisms, preclinical evidence for combinatorial trials using RAF inhibitors as the building blocks, and the new challenges that are arising.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据